ChomiX Biotech Completes Tens of Millions of Yuan in Pre-A+ Financing
In May 2023, Nanjing ChomiX Biotech Co., Ltd. (hereinafter referred to as “ChomiX Biotech”) announced the completion of tens of millions of yuan in Pre-A+ financing. This round was led by TYZS Capital, with follow-on investments from existing shareholders Shuimu Venture Capital and Xiaochi Capital.
T-Capital acted as the financial advisor for ChomiX Biotech in this round and for subsequent financing, providing financial advisory, consulting, and HR services to support the company’s financing efforts.
This round of financing will be primarily used to improve the company’s R&D platform and team capabilities, carry out large-scale screening based on the established lead drug screening platform, and advance subsequent lead compound optimization.
This marks another round of market funding for ChomiX Biotech following the completion of its tens-of-millions-of-yuan Pre-A financing in May 2022.
Project Overview
ChomiX Biotech is a biotechnology company focused on the preclinical development of small-molecule innovative drugs. With chemical proteomics technology at its core, the company is engaged in intracellular innovative drug lead compound screening and drug target discovery.
Since starting operations in 2021, the company has established multiple cross-disciplinary technology platforms, including chemical biology, bioinformatics, medicinal chemistry, and molecular and cellular biology, and has formed a technical foundation that includes core technology patents and a hardware R&D platform.
The company is committed to promoting the industrial application of chemical proteomics technology in new drug R&D. Through drug target discovery and lead compound screening, it aims to accelerate innovative drug discovery and explore R&D opportunities for traditionally “undruggable” targets.
Core Technology: Chemical Proteomics Drives Drug Discovery into Live Cell Systems
Traditional drug discovery technologies largely rely on purified proteins, which limits drug discovery for some disease-related targets.
ChomiX Biotech uses chemical proteomics as its core, further expanding drug discovery to live cell systems.
The company’s DIA-ABPP technology platform enables new binding pocket and ligand discovery for endogenous target proteins in live cells, and is particularly suitable for undruggable targets that lack structural research.
According to information provided by the company, the platform currently covers:
- Over 10,000 proteins;
- Over 40,000 binding sites;
- Thousands of covalent molecules with structural diversity.
This data provides a foundation for innovative drug structure discovery and subsequent lead compound development.
TED-ChomiX Platform Supports Target Discovery and Mechanism Research
In addition to the DIA-ABPP platform, ChomiX Biotech has also established the TED-ChomiX technology platform.
This platform can directly identify the protein targets of bioactive molecules in disease-related cells or tissues, and is used for:
- Drug target discovery;
- New mechanism research;
- Off-target protein analysis.
Through the intersection of chemical biology, bioinformatics, and medicinal chemistry, the company has further improved its technology system from target discovery to lead compound screening.
Financing to be Used for R&D Platform and Lead Compound Development
According to the company, this round of financing will be mainly used for three aspects:
1. Improving the R&D Platform
Further build and improve technical capabilities in chemical proteomics, preclinical medicinal chemistry R&D, and AI-assisted data mining.
2. Strengthening the Core Team
Continue to supplement and improve professional talent and technical teams in chemical proteomics, medicinal chemistry, and bioinformatics.
3. Advancing Lead Drug Screening and Optimization
Utilize the established lead drug screening platform to carry out large-scale screening and conduct subsequent structural optimization of the screened lead compounds.
Past Year: Continuous Advancement of Platform Construction and Industrial Cooperation
Prior to this financing round, ChomiX Biotech had already achieved multiple technical and business milestones.
The company completed the construction of a covalent drug lead compound discovery platform in cells and collaborated with Nanjing PharmaBlock Co., Ltd. to complete the screening of the first batch of molecular libraries for specific targets. Structural optimization is currently underway, and several related patents have been filed.
At the same time, the company has built a drug-like molecule library with thousands of structurally diverse covalent molecules.
In terms of industrial cooperation, ChomiX Biotech has established long-term collaborations with over 80 universities, hospitals, research institutes, and several biopharmaceutical companies in the area of innovative drug target discovery.
Collaborating companies include ACXEL, Gan & Lee Pharmaceuticals, and Hansoh Pharma.
Professional Team and Research Resources
Founding team members of ChomiX Biotech have studied and worked at universities such as Peking University, Rockefeller University, and the University of California, San Diego.
The company’s chief scientist is Professor Chu Wang from Peking University, whose research direction is related to chemical proteomics.
The company’s scientific advisory board is led by Academician Zijian Guo of Nanjing University and brings together many scholars in the field of chemical biology in China.
The company hopes to promote the industrial application of chemical proteomics technology and further accelerate innovative drug discovery through cooperation with universities, research institutes, and pharmaceutical companies.
Investors
TYZS Capital
This round of financing was led by TYZS Capital.
Founded in 2014, TYZS Capital is an independent venture capital institution under Tigermed, mainly focusing on equity investment in early-stage and growth-stage healthcare companies.
According to company information, TYZS Capital’s investment portfolio covers medical devices, biopharmaceuticals, CROs, and health foods.
Shuimu Venture Capital
Shuimu Venture Capital is a professional investment institution for the industrialization of scientific and technological achievements under the Beijing Tsinghua Industrial Development Research Institute. It relies on the transformation and industrialization resources of related scientific and technological achievements of Tsinghua University for investment.
Its investment directions cover technology innovation fields such as healthcare, advanced manufacturing, hydrogen energy, and integrated circuits.
Xiaochi Capital
Hangzhou Xiaochi Private Equity Fund Management Co., Ltd. is a venture capital institution focusing on early-stage life science investment, with a key focus on innovative projects in life sciences, medical technology, and with high technical barriers and clinical needs.
T-Capital: Financial Advisor for ChomiX Biotech’s Current and Subsequent Financing
T-Capital acted as the financial advisor for ChomiX Biotech’s current and subsequent financing.
During this financing process, T-Capital provided financial advisory, consulting, and HR services to ChomiX Biotech, assisting the company in connecting with capital resources and advancing financing work.
T-Capital is a boutique investment bank focusing on the broad healthcare field, providing investment banking services such as:
- Equity financing;
- M&A and restructuring;
- Divestitures and spin-offs;
- Licensing and joint ventures;
- Cross-border transactions;
T-Capital focuses on healthcare companies with technological or business model breakthroughs, serving fields including emerging technologies, medical devices, medical diagnostics, high-value consumables, new drug R&D, healthcare services, consumer health, and digital health.
Project Value
ChomiX Biotech’s core business is at the intersection of chemical proteomics and innovative drug discovery.
The company provides technical support for the preclinical development of small-molecule innovative drugs through target discovery, binding site discovery, and lead compound screening in live cell systems.
This round of financing will further support the construction of the company’s R&D platform, talent team, and lead compound development capabilities.
From a project development path perspective, ChomiX Biotech is gradually establishing its technical and industrialization capabilities around:
Chemical Proteomics Technology → Drug Target Discovery → Lead Compound Screening → Structural Optimization → Preclinical Development of Innovative Drugs
About ChomiX Biotech
Nanjing ChomiX Biotech Co., Ltd. was founded in 2021 and is a biotechnology company focused on the preclinical development of small-molecule innovative drugs.
With chemical proteomics at its core, the company carries out intracellular innovative drug lead compound screening and target discovery, and has established cross-disciplinary technology platforms in chemical biology, bioinformatics, medicinal chemistry, and molecular and cellular biology.
The company holds a number of core technology patents and a hardware R&D platform, and has established collaborations with multiple drug R&D companies, universities, and research institutions, including Nanjing PharmaBlock Co., Ltd.
About T-Capital
T-Capital is a boutique investment bank focusing on the broad healthcare field.
The company provides investment banking services such as equity financing, M&A and restructuring, divestitures and spin-offs, licensing and joint ventures, and cross-border transactions, and is committed to connecting capital with high-quality healthcare companies, as well as domestic and international industrial resources.
T-Capital focuses on emerging technologies, medical devices, medical diagnostics, high-value consumables, new drug R&D, healthcare services, consumer health, and digital health, and helps healthcare companies obtain funding, technology, and industrial cooperation resources through professional capital advisory services.
Project Basic Information
| Item | Information |
|---|---|
| Project Company | Nanjing ChomiX Biotech Co., Ltd. |
| Financing Round | Pre-A+ Round |
| Financing Time | May 2023 |
| Financing Size | Tens of Millions of Yuan |
| Lead Investor | TYZS Capital |
| Follow-on Investors | Shuimu Venture Capital, Xiaochi Capital |
| Use of Funds | R&D platform construction, team capability building, lead drug screening, and lead compound optimization |
| Core Technology | Chemical Proteomics |
| Main Business | Drug target discovery, lead compound screening, preclinical development of small-molecule innovative drugs |
| T-Capital’s Role | Financial advisor for this round and subsequent financing |
| T-Capital’s Services | Financial advisory, consulting, and HR services |
Related Services
This project is related to the following service areas of T-Capital:
- Equity Financing: Provide financing strategy, capital matchmaking, and transaction execution support for healthcare companies.
- Innovative Drug Financing: Provide capital advisory services around innovative drug R&D, drug discovery, and biopharmaceutical technology platforms.
- Healthcare Investment Banking: Connect companies, capital, and industrial resources to support the capital needs of companies at different stages of development.
- Licensing and Strategic Cooperation: Provide transaction services for licensing, co-development, etc., around innovative drug assets, technology platforms, and industrial resources.